In a recent article, entitled Are Pax proteins potential therapeutic targets in kidney disease and cancer?, Dr. Gregory R. Dressler of the University of Michigan, states that “the Pax family of proteins represents new pharmaceutical targets that merit exploration and further development”, and that “combining Pax inhibitors with other chemotherapeutic drugs may improve their efficacy”. A link to the article can be found here.

Disclosure: Dr. Dressler has served as a paid consultant for Genentech and Morrison and Foerster with respect to the patent infringement case filed by Phigenix.